KORU Medical reports record Q4 revenue of $8.8M (+23% YoY); issues 2025 guidance $38-39M

KORU Medical Systems, Inc.

Q4 net revenue $8.8M (+23% YoY); full year $33.6M (+18% YoY).
Q4 gross margin 62.9% (+260 bps); full year 63.4% (+480 bps).
Net loss improved to $1.6M (Q4) and $6.1M (full year); adjusted EBITDA loss narrowed.
Cash $9.6M at Dec 31; Q4 cash flow positive $0.8M; 2025 guidance: revenue $38-39M, gross margin 61-63%, operational cash flow positive.
Novel Therapies segment renamed Pharma Services and Clinical Trials (PST), effective Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.